Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #10418
Ace Report Cover Hand & Wrist

No significant difference for improvement of erosive hand OA pain between adalimumab and placebo


Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial

Osteoarthritis Cartilage. 2018 Jul;26(7):880-887. doi: 10.1016/j.joca.2018.02.899

Contributing Authors: LL Laslett G Jones N Bellamy P Bird D Aitken F Pan IK Haugen P Otahal

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

43 patients with erosive hand osteoarthritis were included in a crossover, randomized design to evaluate the efficacy of adalimumab as a treatment option. Patients were randomized to the order in which they received intervention with either adalimumab or placebo for 12 weeks. There was an 8-week washout period between treatment phases. Improvement in patient-reported pain, stiffness, and function ...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.